Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on September 8, 2021. The filing serves as a Regulation FD disclosure regarding new clinical data for the Company's lead oncology program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or quarterly results.
Material Changes and Clinical Updates
- Clinical Program: The Company announced new data for onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab.
- Indication: The data pertains to the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
- Investor Communication: A corporate presentation was scheduled for September 8, 2021, at 4:00 pm ET to discuss these results.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the standard clinical development context. The information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the specific efficacy and safety data points for onvansertib in the KRAS-mutated mCRC population as detailed in the attached press release (Exhibit 99.1).
- Review the Corporate Presentation (Exhibit 99.2) for management's interpretation of the clinical data and potential next steps for the program.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not disclose liquidity metrics.